U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Qiangen Wu
  1. Science & Research (NCTR)

Qiangen Wu Ph.D., DABT
Leadership Role

Visiting Scientist/Staff Fellow — Division of Biochemical Toxicology

No photo available.


Qiangen Wu, Ph.D., DABT
(870) 543-7121
[email protected]  

Back to NCTR Principal Investigator page


About  |  Publications | Lab Members


Background

Dr. Qiangen Wu received a B.S. degree in preventive medicine from Central South University Xiangya School of Medicine. He earned a Ph.D. in occupational and environmental health from Fudan University School of Public Health and worked as a lecturer for a year in the same university. 

Dr. Wu started his postdoctoral training at the Division of Biochemical Toxicology (DBT) at FDA’s National Center for Toxicological Research (NCTR), where he investigated the induction of DNA damage and repair by the anti-HIV drug zidovudine. Dr. Wu continued his carcinogenesis research at the Department of Environmental Health at Indiana University Bloomington, where he primarily investigated the mechanisms underlying the development of pancreatic cancer by perfluorooctanoic acid in mice. He expanded his research in the Oxidative Stress Environmental Analysis Core Laboratory by studying reactive oxygen species and their biological effects using high performance liquid chromatography-tandem mass spectrometry.  

In 2015, Dr. Wu was recruited by the Analytical Chemistry Support Group at DBT/NCTR as an FDA visiting scientist/staff fellow, where he worked on multiple projects funded by NCTR, the Center for Tobacco Products, and the National Toxicology Program using mass spectrometry. In October 2019, Dr. Wu became a member of the Inhalation Toxicology Core group to conduct tobacco toxicological research. Dr. Wu was certified as a toxicologist by the American Board of Toxicology in 2013 and recertified in 2018. His research efforts have resulted in more than 50 papers published in peer-reviewed journals.

Research Interests

Dr. Wu’s research mainly focuses on the metabolic activity pathways leading to the toxicity and tumorgenicity of FDA-regulated products—especially tobacco products. He investigates the metabolism of toxic chemicals that lead to cytotoxicity, genotoxicity, and carcinogenicity. Using tandem mass spectrometry and high-resolution mass spectrometry, Dr. Wu investigates the formation of the exogenous and endogenous DNA adducts and elucidates the mechanism of tumorgenicity mediated by free radical or nucleophilic metabolites after exposure to carcinogens. Currently, Dr. Wu is working on the effects of vehicles on the pharmacokinetics profile of nicotine in rats following nose-only inhalation exposure.

Using mass spectrometry, Dr. Wu is also evaluating the pharmacokinetics of cannabidiol and its major metabolites in rats upon dermal exposure and in pregnant rats and their pups after oral cannabidiol administration.
 

Professional Societies/National and International Groups 

American Board of Toxicology
Diplomate
2013 - Present (Recertification in 2018)

American Society for Mass Spectrometry
Member
2020 – Present

Society of Toxicology
Member
2010 – Present

Selected Publications

Toxicity of Ortho-phthalaldehyde Aerosols in a Human In Vitro Airway Tissue Model.
Wang Y., Wu Q., Muskhelishvili L., Davis K., Wynne R., Tripathi P., Bryant M., Rua D., and Cao X.
Chem Res Toxicol. 2021, 34(3):754-66. DOI: 10.1021/acs.chemrestox.0c00379.

In vitro Dosimetry Analyses for Acrolein Exposure in Normal Human Lung Epithelial Cells and Human Lung Cancer Cells.
Xiong R.*, Wu Q.*, Bryant M., Rosenfeldt H., Healy S., and Cao X.
Environ Toxicol Pharmacol 2021, 83:103576. DOI: 10.1016/j.etap.2020.103576.

Performance of High-Throughput CometChip Assay Using Primary Human Hepatocytes: A Comparison of DNA Damage Responses with In Vitro Human Hepatoma Cell Lines and In Vivo Rodent Liver Tissues.
Seo J.E., Wu Q., Bryant M.S., Ren L., Shi Q., Mei N., Manjanatha M., and Guo X.
Arch Toxicol. 2020, DOI: 10.1007/s00204-020-02736-z.

The Role of Hepatic Cytochrome P450s in the Cytotoxicity of Sertraline.
Chen S., Wu Q., Li X., Li D., Fan M., Ren Z., Bryant M.S., Mei N., Ning B., and Guo L.
Arch Toxicol. 2020, DOI: 10.1007/s00204-020-02753-y.

Apoptosis Contributes to the Cytotoxicity Induced by Amodiaquine and its Major Metabolite N-Desethylamodiaquine in Hepatic Cells.
Tang Y., Wu Q., Beland F.A., Chen S., and Fang JL.
Toxicol In Vitro. 2020, DOI: 10.1016/j.tiv.2019.104669.

Effects of Cellular Differentiation in Human Primary Bronchial Epithelial Cells: Metabolism of 4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone.
Qin Q.*, Wu Q.*, Wang Y., Xiong R., Guo L., Fu X., Rosenfeldt H., Bryant M., and Cao X.
Toxicol In Vitro. 2019, 55, 185-194. (*equal contribution) DOI: 10.1016/j.tiv.2018.12.006.

Primary and Secondary Pyrrolic Metabolites of Pyrrolizidine Alkaloids Form DNA Adducts in Human A549 Cells.
He X., Xia Q., Wu Q., Tolleson W.H., Lin G., and Fu P.P.
Toxicol In Vitro. 2019, 54, 286-294. DOI: 10.1016/j.tiv.2018.10.009.

Quantitative Comparison of In Vitro Genotoxicity Between Metabolically Competent HepaRG Cells and HepG2 Cells Using the High-Throughput High-Content CometChip Assay.
Seo J.E., Tryndyak V., Wu Q., Dreval K., Pogribny I., Bryant M., Zhou T., Robison T.W., Mei N., and Guo X.
Arch Toxicol. 2019, 93, 1433-1448. DOI: 10.1007/s00204-019-02406-9.

Evaluating Mode of Action of Acrolein Toxicity in an in vitro Human Airway Tissue Model.
Xiong R., Wu Q., Muskhelishvili L., Davis K., Shemansky J.M., Bryant M., Rosenfeldt H., Healy S.M., and Cao X.
Toxicol Sci. 2018, 166, 451-464. DOI: 10.1093/toxsci/kfy226.

The Role of Hepatic Cytochrome P450s in the Cytotoxicity of Dronedarone.
Chen S., Wu Q., Ning B., Bryant M., and Guo L.
Arch Toxicol. 2018, 92, 1969-1981. DOI: 10.1007/s00204-018-2196-x.

Toxaphene-Induced Mouse Liver Tumorigenesis is Mediated by the Constitutive Androstane Receptor.
Wang Z., Li X., Wu Q., Lamb J.C., and Klaunig J.E.
J Appl Toxicol. 2017, 37(8): 967-975. DOI: 10.1002/jat.3445.

The Role of CYP 3A4 and 1A1 in Amiodarone-Induced Hepatocellular Toxicity.
Wu Q., Ning B., Xuan J., Ren Z., Guo L., and Bryant M.S.
Toxicol Lett. 2016, 253: 55-62. DOI: 10.1016/j.toxlet.2016.04.016.

Perfluorooctanoic Acid Exposure Triggers Oxidative Stress in the Mouse Pancreas.
Kamendulis L.M., Wu Q., Sandusky G.E., and Hocevar B.A.
Toxicol Rep. 2014, 1: 513-521. DOI: 10.1016/j.toxrep.2014.07.015.

Differential Gene Expression in Human Hepatocyte Cell Lines Exposed to the Antiretroviral Agent Zidovudine.
Fang J.L., Han T., Wu Q., Beland F.A., Chang C.W., Guo L., and Fuscoe J.
Arch Toxicol. 2014, 88: 609-623. DOI: 10.1007/s00204-013-1169-3.

Role of DNA Repair Pathways in Response to Zidovudine-Induced DNA Damage in Immortalized Human Liver THLE2 Cells.
Wu Q., Beland F.A., Chang C., and Fang J.L.
Int J Biomed Sci. 2013, 9: 18-25. PMID: 23675285.

Cytotoxicity and Inhibitory Effects of Low-Concentration Triclosan on Adipogenic Differentiation of Human Mesenchymal Stem Cells.
Guo L.-W.*, Wu Q.*, Green B., Nolen G., Shi L., LoSurdo J., Deng H., Bauer S., Fang J.L., and Ning B.
Toxicol Appl Pharm. 2012, 262: 117-123. (*equal contribution) DOI: 10.1016/j.taap.2012.04.024.

XPC is Essential for Nucleotide Excision Repair of Zidovudine-Induced DNA Damage in Human Hepatoma Cells.
Wu Q., Beland F.A., Chang C., and Fang J.L.
Toxicol Appl Pharmacol. 2011, 251: 155-162. DOI: 10.1016/j.taap.2010.12.009.

Lab Members

Contact Information for all lab members:
(870) 543-7121
[email protected] 

Seonggi Min, Ph.D.
Staff Fellow

Gregory J Pellar, Ph.D.
Staff Fellow

Yunan Tang, Ph.D., DABT
Staff Fellow

Dong-Jin Yang, MS
Staff Fellow

Jinghai Yi, Ph.D.
Mechanical Engineer


Contact Information
Qiangen Wu
(870)543-7121
Back to Top